Last updated: November 16, 2026
AMX0035, marketed in the United States as Relyvrio, has lost its commercial foundation after the Phase 3 PHOENIX trial failed to confirm benefit in amyotrophic lateral sclerosis (ALS). Amylyx Pharmaceuticals withdrew Relyvrio from the U.S. and Canadian markets in 2024. New-patient access ended, and the product’s forward commercial market is effectively zero in those jurisdictions. Development value now depends on whether the AMX0035 combination can generate positive evidence in other neurodegenerative diseases or regain a regulatory pathway in ALS. [1-4]
What is AMX0035 and how does it work?
AMX0035 is an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol. It was developed to reduce cellular stress through two complementary mechanisms:
- Sodium phenylbutyrate is intended to reduce endoplasmic-reticulum stress.
- Taurursodiol, also known as tauroursodeoxycholic acid or TUDCA, is intended to protect mitochondrial function and reduce apoptosis-related signaling.
The product was supplied as a powder for oral suspension. Its initial development target was ALS, a fatal neurodegenerative disease with limited disease-modifying treatment options.
The product was approved under the brand name Relyvrio in September 2022. The FDA approval relied primarily on the CENTAUR trial and its open-label extension, while the agency required a confirmatory study under the accelerated-approval framework. [1]
What is the current AMX0035 development status?
AMX0035 is no longer commercially available in the United States or Canada for routine ALS treatment.
Key development and regulatory timeline
| Date |
Event |
Commercial or regulatory effect |
| 2016-2019 |
CENTAUR Phase 2 trial conducted in ALS |
Generated the clinical data supporting later regulatory filings |
| 2020 |
CENTAUR results published |
Reported a slower rate of functional decline and an overall-survival signal |
| 2022 |
FDA approved Relyvrio for ALS |
Approval granted under the accelerated-approval pathway |
| 2022 |
Health Canada authorized Albrioza |
Canadian approval for adult ALS patients |
| 2023-2024 |
PHOENIX confirmatory trial reported |
Failed to meet its primary efficacy endpoint |
| March 2024 |
Amylyx announced voluntary withdrawal in the U.S. and Canada |
New-patient starts ended |
| April 2024 |
U.S. commercial withdrawal completed |
Relyvrio no longer sold through normal commercial channels |
| October 2024 |
Canadian market withdrawal completed |
Albrioza no longer available through the Canadian commercial market |
Amylyx stated that patients already receiving therapy could continue through a transition and expanded-access process for a limited period. The company also stated that it would not seek further regulatory approval for AMX0035 in ALS based on the PHOENIX result. [2,3]
Why did AMX0035 fail in the PHOENIX trial?
PHOENIX did not reproduce the clinical benefit observed in CENTAUR.
The Phase 3 trial enrolled approximately 664 people with ALS and evaluated change in the ALS Functional Rating Scale-Revised, or ALSFRS-R. The study did not meet its prespecified primary endpoint. The results did not show a statistically persuasive treatment effect on functional decline, and secondary analyses did not provide a sufficient basis to preserve the ALS indication. [2]
CENTAUR versus PHOENIX
| Measure |
CENTAUR |
PHOENIX |
| Development stage |
Phase 2 |
Phase 3 confirmatory |
| Approximate enrollment |
137 |
664 |
| Primary clinical focus |
ALS functional decline |
ALS functional decline |
| Outcome |
Positive signal reported |
Primary endpoint not met |
| Regulatory role |
Supporting evidence |
Required confirmatory evidence |
| Result for approval |
Contributed to accelerated approval |
Failed to confirm benefit |
The contrast between the two studies materially weakened the clinical and commercial case for AMX0035. The FDA did not convert the accelerated approval into a conventional approval before withdrawal.
When did AMX0035 lose exclusivity and commercial access?
AMX0035 did not reach a conventional patent-expiration-driven loss of exclusivity. Its market ended because of failed confirmatory efficacy evidence and voluntary withdrawal.
The relevant dates are:
- U.S. approval: September 29, 2022.
- U.S. withdrawal announcement: March 4, 2024.
- U.S. commercial withdrawal: April 2024.
- Canadian withdrawal completion: October 2024.
Relyvrio’s withdrawal is different from a standard generic-entry event. Generic manufacturers did not need to wait for patent expiration to enter a large U.S. market because Amylyx removed the product from commercial distribution.
The FDA’s accelerated approval pathway also limited the product’s regulatory durability. A failed post-approval trial can lead to withdrawal even when patent protection remains in force. [1,2]
What is the Orange Book status of Relyvrio?
Relyvrio was approved under NDA 217026. The product’s FDA approval was withdrawn at the sponsor’s request after the failed confirmatory trial.
The commercial importance of Orange Book listing was limited by three factors:
- The product was withdrawn before a durable generic market developed.
- The failed PHOENIX study removed the regulatory basis for continued commercial promotion.
- The active-ingredient combination contains widely known chemical entities, reducing the practical value of composition claims unless they cover a specific formulation, ratio, dosage form, or manufacturing process.
Publicly available product information does not establish a commercially meaningful U.S. patent barrier capable of supporting future Relyvrio sales. The key protection issue was regulatory and clinical viability rather than a conventional Paragraph IV patent contest.
Were there Paragraph IV challenges or patent litigation involving AMX0035?
No major public Paragraph IV generic challenge or patent litigation campaign became a central market event for Relyvrio before withdrawal.
The absence of a significant Paragraph IV dispute reflects the product’s short commercial life and the lack of an established generic-entry opportunity. The likely legal questions for any future copy would include:
- Whether a proposed product uses the same fixed-dose combination.
- Whether it uses an equivalent formulation or delivery system.
- Whether a listed patent covers the composition, ratio, dosage, or method of treatment.
- Whether the FDA’s withdrawal status permits or complicates a new abbreviated filing.
- Whether the sponsor has enforceable formulation or process claims outside the United States.
A future developer would face a greater clinical and regulatory burden than a typical ANDA filer because the core efficacy evidence for ALS is now negative at the confirmatory-trial level.
What formulations and manufacturing technology are protected?
The commercial product used a combination of sodium phenylbutyrate and taurursodiol in an oral suspension formulation. Potential intellectual-property coverage can include:
- Fixed-dose combination composition.
- Specific molar or weight ratios.
- Powder-for-suspension presentation.
- Stability and moisture-control technology.
- Taste-masking and powder-dispersion properties.
- Manufacturing and packaging processes.
- Dosing regimens for ALS or other neurodegenerative diseases.
The active ingredients themselves are established compounds. That limits the scope of any claim directed only to sodium phenylbutyrate or taurursodiol as chemical entities. The strongest remaining protection, if enforceable, would likely relate to the combination, formulation, dosage form, or use in a defined disease population.
No patent estate can overcome a failed confirmatory trial in ALS unless a sponsor generates new clinical evidence and obtains a new regulatory basis.
What is the biosimilar risk for AMX0035?
Biosimilar risk is not relevant because AMX0035 is a small-molecule combination product, not a biologic. The relevant competitive threats are:
- Generic sodium phenylbutyrate.
- Generic taurursodiol or TUDCA products.
- Compounded combinations.
- Nutraceutical TUDCA products.
- Alternative ALS therapies such as riluzole, edaravone, tofersen for SOD1-mutated ALS, and investigational therapies.
The regulatory status of a compounded or supplement product would differ materially from an FDA-approved AMX0035 equivalent. A supplement containing TUDCA would not be interchangeable with Relyvrio and would not carry the same ALS indication.
Which companies are challenging or replacing AMX0035 in ALS?
No company is directly replacing AMX0035 with an equivalent fixed-dose combination. Competition has shifted toward therapies with different mechanisms and regulatory positions.
| Product or program |
Sponsor |
Position relative to AMX0035 |
| Riluzole |
Multiple manufacturers |
Long-standing ALS standard of care |
| Radicava and Radicava ORS |
Mitsubishi Tanabe Pharma |
Approved ALS therapy with intravenous and oral formulations |
| Qalsody |
Biogen and Ionis |
Approved for SOD1-mutation-associated ALS |
| Tofersen follow-on development |
Biogen and academic groups |
Focused on genetically defined ALS |
| Investigational ALS programs |
Multiple biotechnology companies |
Compete for clinical-trial enrollment and treatment share |
Amylyx’s post-withdrawal strategy moved away from commercializing AMX0035 in ALS. The company has focused on other development assets, including AMX0114, an antisense oligonucleotide program directed at calpain-2 in ALS. AMX0114 is a separate investigational program and does not restore AMX0035’s market position.
What licensing deals and partnerships affected AMX0035?
Amylyx retained primary control of AMX0035 commercialization in the United States and Canada. The company’s commercial strategy depended on internal commercialization and regulatory execution rather than a major global pharmaceutical licensing transaction.
The absence of a large ex-U.S. licensing deal reduced the opportunity to transfer AMX0035’s commercial risk to a larger partner after PHOENIX. It also left the company responsible for withdrawal costs, patient transition arrangements, and the loss of product revenue.
How much revenue was exposed to the AMX0035 withdrawal?
Relyvrio became Amylyx’s principal commercial product after FDA approval. Amylyx reported approximately $381.6 million in net product revenue for 2023, largely reflecting Relyvrio sales. [5]
The withdrawal eliminated the company’s principal commercial revenue source in the United States and Canada. Revenue exposure was concentrated in:
- Prescription sales to ALS patients.
- Reimbursement from U.S. commercial insurers and government programs.
- Canadian provincial and private reimbursement.
- Patient-support and distribution channels linked to the approved product.
Market projection
| Scenario |
2025-2027 market outlook |
Probability assessment |
| U.S. and Canada commercial market |
Effectively zero for Relyvrio |
High |
| Continued expanded access |
Limited, temporary, noncommercial |
High |
| New ALS approval for AMX0035 |
Unlikely without new positive evidence |
Low |
| New indication outside ALS |
Possible but unproven |
Low to moderate |
| Generic or compounded substitution |
Limited and fragmented |
Moderate |
| Global re-entry through another regulator |
Uncertain and commercially small |
Low |
A reasonable base-case projection is no material commercial revenue from AMX0035 in the United States or Canada after the 2024 withdrawal. Any future value would come from a new indication, new clinical evidence, or a separate regional regulatory strategy. That value should be modeled as development-option value rather than as a continuing ALS franchise.
How strong is the AMX0035 patent estate?
The AMX0035 patent estate has limited practical strength because patent rights are subordinate to regulatory and clinical viability.
Strength assessment
| Factor |
Assessment |
| Chemical-entity protection |
Weak to limited because both active ingredients are established compounds |
| Combination protection |
Potentially meaningful if claims cover a defined ratio or combination |
| Formulation protection |
Potentially meaningful for a specific oral powder or suspension |
| Method-of-use protection |
Limited by the failed ALS confirmatory study |
| Manufacturing protection |
Possible, but unlikely to support a large standalone market |
| Orange Book leverage |
Low after commercial withdrawal |
| Litigation leverage |
Low absent an active commercial entrant |
| Remaining asset value |
Primarily option value in new indications |
Patent protection may extend beyond the 2024 commercial withdrawal date, but expiration alone does not determine product value. For AMX0035, the principal barrier is the need for credible clinical differentiation, not simply the ability to exclude a generic manufacturer.
What generic launch risks exist for AMX0035?
A future generic or alternative product would face several possible launch paths:
- An ANDA referencing the approved product, if the withdrawal status and FDA regulatory records support that pathway.
- A 505(b)(2) application using literature and existing safety data.
- A new drug application supported by new clinical evidence.
- Compounding or supplement distribution outside the approved-drug framework.
The most realistic commercial threat is not a conventional high-volume generic launch. It is substitution by lower-cost sodium phenylbutyrate, TUDCA products, or compounded combinations. Those products would not automatically reproduce Relyvrio’s approved labeling, reimbursement, or clinical evidence.
How does AMX0035 compare with competing ALS drugs?
| Product |
Active ingredient or mechanism |
Regulatory position |
Commercial status |
| Relyvrio |
Sodium phenylbutyrate plus taurursodiol |
Withdrawn after failed PHOENIX |
No routine U.S. or Canadian commercial market |
| Riluzole |
Glutamate-related mechanism |
Approved |
Broad generic availability |
| Radicava |
Edaravone |
Approved |
Commercially available |
| Qalsody |
Tofersen, antisense oligonucleotide |
Approved for SOD1-ALS |
Genotype-defined market |
| AMX0114 |
Antisense oligonucleotide targeting calpain-2 |
Investigational |
No approved revenue |
Relyvrio had the advantage of oral administration and broad ALS labeling before withdrawal. Its disadvantage was the failure to confirm efficacy in a larger Phase 3 trial. Riluzole has the strongest generic-market position, while Qalsody has a narrower but biomarker-defined treatment population.
Key Takeaways
- AMX0035 is the sodium phenylbutyrate and taurursodiol combination formerly sold as Relyvrio.
- The FDA approved Relyvrio in September 2022 under accelerated approval.
- The PHOENIX Phase 3 trial failed to confirm the CENTAUR results.
- Amylyx withdrew Relyvrio from the U.S. and Canada in 2024.
- The product has no meaningful continuing commercial market in those jurisdictions.
- Biosimilar risk does not apply because AMX0035 is a small-molecule combination, not a biologic.
- No major Paragraph IV litigation became a defining event before withdrawal.
- Remaining IP value is concentrated in combination, formulation, manufacturing, and potential new-use claims.
- Any future AMX0035 value depends on new clinical evidence or a new indication.
- The most defensible 2025-2027 forecast is zero material U.S. and Canadian product revenue.
FAQs
Can AMX0035 still be prescribed for ALS?
Routine commercial prescribing ended after Amylyx withdrew Relyvrio in the United States and Albrioza in Canada. Limited access may have continued through transition or expanded-access arrangements.
Will AMX0035 return to the U.S. market?
A return would require a new regulatory and clinical basis. The failed PHOENIX trial makes a near-term commercial relaunch unlikely.
Is TUDCA the same as Relyvrio?
No. TUDCA is one component of Relyvrio. Relyvrio was a specific pharmaceutical combination containing taurursodiol and sodium phenylbutyrate.
Can a generic manufacturer launch sodium phenylbutyrate and taurursodiol?
A manufacturer could pursue an applicable FDA pathway, but an equivalent product would need to satisfy regulatory, formulation, labeling, and intellectual-property requirements.
What is the investment value of AMX0035 after withdrawal?
The original ALS commercial value is largely extinguished. Any residual value is an option tied to new indications, regional rights, formulation IP, or follow-on assets rather than ongoing Relyvrio sales.
References
- U.S. Food and Drug Administration. (2022). FDA approves oral phenylbutyrate and taurursodiol for treatment of amyotrophic lateral sclerosis. https://www.fda.gov
- Amylyx Pharmaceuticals, Inc. (2024). Amylyx Pharmaceuticals announces topline results from PHOENIX trial of AMX0035 in ALS. https://www.amylyx.com
- Amylyx Pharmaceuticals, Inc. (2024). Amylyx Pharmaceuticals announces decision to voluntarily withdraw Relyvrio/Albrioza. https://www.amylyx.com
- U.S. Food and Drug Administration. (2024). Relyvrio prescribing information and approval history. https://www.accessdata.fda.gov
- Amylyx Pharmaceuticals, Inc. (2024). Annual report for fiscal year 2023. U.S. Securities and Exchange Commission. https://www.sec.gov
- Paganoni, S., Macklin, E. A., Hendrix, S., et al. (2020). Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. New England Journal of Medicine, 383(10), 919-930. https://doi.org/10.1056/NEJMoa1916945